Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
February 14, 2025 - IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, yesterday presented ...
NEW YORK - IN8bio, Inc. (Nasdaq: INAB), a biopharmaceutical company specializing in gamma-delta T cell therapies with a current market capitalization of $23.42 million, has announced encouraging Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback